An Observational Cohort Study of the Safety of Brentuximab Vedotin in the Treatment of Relapsed or Refractory CD30+ Hodgkin Lymphoma and Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma - ARROVEN

Trial Profile

An Observational Cohort Study of the Safety of Brentuximab Vedotin in the Treatment of Relapsed or Refractory CD30+ Hodgkin Lymphoma and Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma - ARROVEN

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2016

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Anaplastic large cell lymphoma; Hodgkin's disease
  • Focus Adverse reactions
  • Acronyms ARROVEN
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 14 Oct 2013 New trial record
    • 11 Oct 2013 Results have been presented at the 9th International Symposium on Hodgkin Lymphoma (ISHL) according to a : Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top